Eli Lilly And Company Announces Detailed Results From Phase 3 ACHIEVE-4 Trial Evaluating Foundayo Compared To Insulin Glargine
Eli Lilly's Phase 3 ACHIEVE-4 trial showed Foundayo (orforglipron) was non-inferior to insulin glargine in reducing major cardiovascular events in type 2 diabetes patients with obesity. Foundayo also improved A1C, weight, and other cardiometabolic health measures. The trial, presented at EASD and published in The Lancet, involved 2,749 participants across multiple countries.
How this was made
The 30-second read
Why it matters
The trial demonstrates non‑inferior MACE outcomes and improvements in weight, blood pressure, and kidney function, positioning Foundyo for broader adoption.
Market read
First‑report positive cardiovascular outcomes for a major diabetes drug could drive a short‑term rally in LLY and influence the broader GLP‑1 market.
What to watch
Regulatory review timelines and reimbursement negotiations could delay commercial impact despite positive data.
Background
Eli Lilly's Foundyo (orforglipron) is an oral GLP‑1 agonist competing with injectable therapies; the ACHIEVE‑4 trial is the largest cardiovascular outcomes study for this class.
Ticker impact
Eli Lilly released detailed Phase 3 ACHIEVE-4 trial results showing cardiovascular safety and metabolic benefits of its oral GLP‑1 drug Foundayo.
upside pressure as investors price in improved cardiovascular outcomes and expanded market potential.
The data are first‑report, statistically significant, and address a major unmet need, which historically moves large‑cap pharma stocks.
Market effects
Strengthens the GLP‑1 class narrative, potentially boosting peers like Novo Nordisk and Pfizer.
U.S. biotech sector may see modest gains; European markets with GLP‑1 exposure could also benefit.
Adds to global diabetes/obesity therapeutic pipeline confidence.
Counterpoint
If the hazard ratios miss statistical significance thresholds, the market may view the data as inconclusive and price could stall.
Key entities
- companyEli Lilly and Company
Pharmaceutical company developing Foundyo.
- productFoundayo (orforglipron)
Oral GLP‑1 receptor agonist under investigation.
